Objectives: To assess ciprofloxacin resistance among Escherichia coli isolates from bacteraemia patients in England in relation to age, sex and Region.
Introduction
Fluoroquinolones are valuable and potent antimicrobials, but are increasingly compromised by mutational resistances that reduce target sensitivity, restrict permeability or increase efflux. 1 We reported previously a steady year-on-year rise in the prevalence of ciprofloxacin resistance in Escherichia coli isolates from bacteraemias in England, from 0.8% in 1990 to 3.7% in 1999. 2 Although low compared with the prevalence rates in many developing countries, 2 these data indicate a disturbing trend. Here, we extended the analysis to 2001, and investigated relationships between resistance and patient demographics.
Materials and methods

Data collection
Voluntary reporting to the Health Protection Agency's LabBase/CoSurv surveillance system captures routine microbiological information on bacteraemias from over 90% of the clinical diagnostic laboratories in England and Wales. 3 Analysis for Staphylococcus aureus, where there is a parallel mandatory reporting scheme, suggests that about two-thirds of bacteraemias are reported. 4 
Data analysis
All reports of E. coli bacteraemia in England, received under the routine reporting scheme during 1995-2001, were extracted for analysis. Overall trends were described either as a ratio of the proportions resistant in two specific years (a risk ratio, RR), or as an average percentage increase between successive years, estimated by a generalized linear model of the binomial family and a log link function. Significance tests were based on logistic regression, and so compared odds ratios. The overall trend was estimated by controlling for Region, sex and age; sex-specific trends were estimated controlling for Region and age; differences between age groups were tested controlling for Region and year; Region-specific trends were estimated controlling for sex and age group. 
Results
During 1995-2001, 8575-11 297 E. coli bacteraemias per annum were reported, with 39.3%-62.3% of the reports including data on ciprofloxacin susceptibility ( Women accounted for 57% of all the E. coli bacteraemia patients reported, but there was a stronger trend of rising resistance among isolates from men (average annual increase 22%; 95% CI: 18-27) than from women (16%; 95% CI: 12-21). By 2001, 8.0% of the E. coli isolates from men were reported to be resistant, compared with 5.5% of those from women ( Table 1 ). The prevalence of resistance also varied with the patient's age (Table 2) , being lowest (<1.5%) in isolates from those aged under 1 year (P ≤ 0.002 for men and P ≤ 0.02 for women compared with all other ages). Resistance among isolates from females peaked in the 1-14 age group (5.1%), but its prevalence was not significantly reduced for older age groups. Among isolates from males, however, resistance clearly peaked in the 15-44 age group, where it was significantly more prevalent than in 45-64-yearolds (P = 0.02) and those aged ≥65 (P < 0.0005).
Discussion
E. coli remains the second most common agent of bacteraemia in England and Wales, after Staphylococcus aureus. Thus, changes in its susceptibility pattern are important, and it is disturbing that ciprofloxacin resistance continues to accumulate in the species.
It was striking also, from this analysis, that although more E. coli bacteraemias occur in women, ciprofloxacin resistance is more prevalent in those from men. We are unaware of any such strong association between resistance and gender having been found previously. A likely factor is that women are anatomically more prone than men to ascending urinary tract infections by the resident gut microflora, with some of these infections leading to bacteraemias. Because such infections are rarer in men (at least until later life, when prostatitis has an impact), relatively more of the fewer E. coli bacteraemias in men are likely to be caused by hospital strains, which may tend to be more resistant than E. coli from the normal gut flora. This hypothesis is supported by the observations, using the same database, that resistance was more prevalent in E. coli isolates from men to gentamicin (RR, 1.30; 95% CI: 1.14-1.50) and ceftazidime (RR, 1.64; 95% CI: 1.34-2.02), both of which are used almost exclusively in hospitals. Conversely, the pattern was reversed for ampicillin (RR, 0.95; 95% CI: 0.93-0.97) and trimethoprim (RR, 0.88; 95% CI: 0.85-0.92), which are oral drugs widely used in the community. Selection in women may also be mitigated by a disinclination to use quinolones in those of child-bearing age.
Routine laboratory data received by the Health Protection Agency offer few insights into the origins of the reported bacteraemias. The British Society for Antimicrobial Chemotherapy's Bacteraemia Surveillance (http://www.bsacsurv.org) does have such data, based on 10 consecutive E. coli bacteraemias and isolates per annum from each of 25 UK and Irish hospitals. Among 482 E. coli isolates in 2001 and 2002, 279 (58%) were from women; and 67% of those from women were community-acquired (<48 h hospitalization) compared with 60% of those from men (P = 0.14). Ciprofloxacin resistance was seen in 7.4% (22/296) of the community-acquired isolates compared with 8.4% (14/166) of those from hospital-acquired infections (P = 0.72). These differences failed to achieve statistical significance but are consistent with the hypothesis that E. coli bacteraemias in men are more likely to be nosocomial, and to be caused by ciprofloxacinresistant organisms. This hypothesis is further supported by an analysis of 861 E. coli bacteraemia episodes treated at a London hospital during 1969-1987. 5 Among hospital-acquired bacteraemias, the Resistances to gentamicin and (in that earlier period) ampicillin were more frequent among the nosocomial cases. The study pre-dated ciprofloxacin, and the resistance rates were not analysed in relation to gender. The relationship between the patient's age and the prevalence of resistance also was notable (Table 2) . Very low resistance rates in those aged <1 year might reflect the lack of fluoroquinolone use in these infants. Since, however, quinolone use should also be limited in the 1-14 year group (where these drugs are only used if their benefits are thought to exceed the arthropathy risks) the relationship is more likely to reflect the fact that neonatal units develop a particular flora that contributes to patient colonization. 6 Table 2 . Ciprofloxacin resistance among bloodstream E. coli isolates from England, related to age and sex, based on pooled data for [1995] [1996] [1997] [1998] [1999] [2000] [2001] Data were omitted where patients' ages were not recorded; hence the totals are lower than those in Table 1 .
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